Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Secord, AA, Barnett, JC, Ledermann, JA, Peterson, BL, Myers, ER, and Havrilesky, LJ. "Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer." Int J Gynecol Cancer 23, no. 5 (June 2013): 846-852.

Full Text

Havrilesky, LJ, Gierisch, JM, Moorman, PG, Coeytaux, RR, Urrutia, RP, Lowery, WJ, Dinan, M, McBroom, AJ, Wing, L, Musty, MD, Lallinger, KR, Hasselblad, V, Sanders, GD, and Myers, ER. "Oral contraceptive use for the primary prevention of ovarian cancer." Evidence report/technology assessment, no. 212 (June 2013): 1-514. (Review)

Scholars@Duke

Havrilesky, LJ, Kulasingam, SL, Jewell, EL, and Cohn, DE. "Comparative effectiveness research in gynecologic oncology." In Principles and Practice of Gynecologic Oncology: Sixth Edition, 503-517. May 8, 2013.

Scholars@Duke

Bolac, CS, Wallace, AH, Broadwater, G, Havrilesky, LJ, and Habib, AS. "The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer." Anesth Analg 116, no. 5 (May 2013): 1041-1047.

Full Text

Hanna, RK, Poniewierski, MS, Laskey, RA, Lopez, MA, Shafer, A, Van Le, L, Crawford, J, Dale, DC, Gehrig, PA, Secord, AA, Havrilesky, LJ, and Lyman, GH. "Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer." Gynecol Oncol 129, no. 1 (April 2013): 74-80.

Full Text

Kulasingam, SL, Havrilesky, LJ, Ghebre, R, and Myers, ER. "Screening for cervical cancer: a modeling study for the US Preventive Services Task Force." J Low Genit Tract Dis 17, no. 2 (April 2013): 193-202.

Full Text

Alvarez, RD, Gray, HJ, Timmins, PF, Gibb, RK, Edelson, M, Fowler, JM, Havrilesky, LJ, McCauley, DL, Nash, JD, Rahaman, J, Rash, JK, Rodabaugh, KJ, Powell, MA, Bristow, RE, Brown, JV, Tewari, D, Cliby, WA, Anastasia, P, Robinson, WR, Shahin, MS, Cantrell, LA, Cloven, NG, Gold, MA, Hope, JM, Muntz, HG, Sorosky, JI, Elkas, JC, Frumovitz, MM, Jewell, E, Spillman, MA, and Naumann, RW. "We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies." Gynecol Oncol 129, no. 1 (April 2013): 3-4.

Scholars@Duke

Havrilesky, LJ, and Abernethy, AP. "Quality of life in ICON7: need for patients' perspectives." Lancet Oncol 14, no. 3 (March 2013): 183-185.

Full Text

Hess, LM, Brady, WE, Havrilesky, LJ, Cohn, DE, Monk, BJ, Wenzel, L, and Cella, D. "Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study." Gynecol Oncol 128, no. 2 (February 2013): 175-180.

Full Text

Secord, AA, Geller, MA, Broadwater, G, Holloway, R, Shuler, K, Dao, N-Y, Gehrig, PA, O'Malley, DM, Finkler, N, and Havrilesky, LJ. "A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer." Gynecologic Oncology 128, no. 1 (2013): 65-70.

Full Text

Pages